Quote:
________________________________________
Do you mean, "Is there any cancer drug for any solid tumor..."
No!
To digress as Biowatch has performed the necessary links to shorthand the way I wish to express my asking of whether there is any drug that meets the PFS endpoint for solid tumors, first using the PFS wording in my referenced message as the subtext Dew put forth in his recent quote:
" PFS is often the preferred primary endpoint in the first-line setting because it removes the subsequent-treatment noisiness inherent in OS".
The Biowatch links suggest the contention, disagreement and incompleteness of "some" implied meaningful endpoint markers/metrics for which I assume a drug Co. may pay 100 million to enunciate, satisfy, and perhaps confuse.
To digress further my relative who has a PHD in the Philosophy of science has spent 25 years as a scholar to qualify for a chance to publish in a recognized science journal the introduction of a single new word which can be used again in other medical publications, so I realize if I add something to this discussion I should put my assumed understood wording in quotes.
Ok, I see it may be just as hard to find the wording to ask the question about the progress the drug companies made in solid tumor uh "eradication" as it is to find a "cure" for cancerous solid tumors.
I assume that the metric wording useful for measuring endpoint "exemplary effectiveness" is further challenged by the increasing recognition that single drugs may have very limited ha, "value" but be precisely necessary in combination with another or multiple drugs also singularly "ineffective". So what kind of metric wording would be recognized for approval of each drug before that drug was "proven" to have a 100 fold effectiveness in new combination with other drugs?.
And so I started out wishing to know what handy metric wording would allow me to judge the merit of a drug, but those metrics which have appeared rather "lame" may
be proven to have been masterfully adequate, as those mediocre metrics masked possible unproven " enhanced merit".
